EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KM who wrote (1741)	2/16/1999 6:31:00 PM
From: Biomaven	Read Replies (1) of 2135

Interesting valuation analysis. I disagree with the way he's used the discount rate, though. Using his methodology, I would use his 50% rate until the drug was approved (3 years) and his 18% rate thereafter, while they build to their maximum sales over 4 years. This gives a $244m PV for the drug ($825m on approval, which seems low), and makes the current stock price about right, given his assumptions. A big issue of course is whether his assumptions are realistic. I think 3 years to two approved drugs is way too optimistic, but that the eventual sales would be quite a bit higher (and more quickly reached) if they perform in humans at all comparably to the way they allegedly perform in mice. If you look at a value assuming the drugs were approved today, even my $825m seems low to me, perhaps by a factor of three or four. Doesn't mean that I think the stock is currently underpriced - I think there's much better value to be had elsewhere in the same area (like CELG and SUGN). Basically I'm skeptical that ENMD can bring these drugs in their present form to market. (Disclosure: I have a very small in-the-money Feb put position, established last week after the rebound at around 25). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next